Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now later-stage tilt small index

Portal Hypertension: later-stage trial registry

3 of 10 indexed Portal Hypertension trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 3 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Portal Hypertension: 10 US clinical trials tracked, 3 recruiting.

Portal Hypertension is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is University of Michigan, running 2 of these trials.

Enrollment posture brief

Registry condition portal-hypertension

OPEN 3 | RECR 30% | LATE 4 | EARLY 1 | RANK #1724 | SPON 2

Nearest open-share peer: Adrenocortical Carcinoma (30% recruiting · 10 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Portal Hypertension (this)30%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Portal Hypertension

Portal Hypertension lists 3 open slots (30% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Portal Hypertension on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Portal Hypertension is recruiting below its size-band peers.

    3 of 10 indexed trials (30%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Portal Hypertension research.

    University of Michigan accounts for 2 of 10 trials (20%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Most Portal Hypertension trials plan to enrol fewer than 100 people.

    Median target enrolment is 70 among the 10 trials that report a genuine target (sentinel values excluded). 6 of those (60%) plan for fewer than 100 participants.

  4. Portal Hypertension research is mostly interventional.

    8 interventional and 2 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21Phase 34

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 3 660 participants

Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal

Thomas Jefferson University

NCT05470205

RECRUITING NA 60 participants

Ultrasound With Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal Hypertension

Mayo Clinic

NCT06797193

RECRUITING 45 participants

Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis

Massachusetts General Hospital

NCT06265272

ACTIVE NOT RECRUITING 52 participants

LiveSMART Trial to Prevent Falls in Patients With Cirrhosis - Supplementary Study

University of Michigan

NCT07140120

ACTIVE NOT RECRUITING Phase 2 30 participants

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Davendra Sohal

NCT05027425

COMPLETED NA 500 participants

Non-invasive Diagnosis of Portal Hypertension With Acoustic Radiation Force Impulse (ARFI)

VA Connecticut Healthcare System

NCT01644656

COMPLETED Phase 3 230 participants

LiveSMART Trial to Prevent Falls in Patients With Cirrhosis

University of Michigan

NCT05794555

COMPLETED Phase 3 213 participants

Prevention of Esophageal Varices by Beta-Adrenergic Blockers

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00006398

COMPLETED Phase 3 70 participants

Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding

Debiovision

NCT00331188

COMPLETED NA 20 participants

Evaluation of 3D Overlay During Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedure

Medical College of Wisconsin

NCT02053571

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 4

Named interventions

Most-linked intervention names on Portal Hypertension records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Sanvar® (vapreotide) Drug
1 trials
Timolol Maleate Drug
1 trials
TIPS with 3D Overlay Procedure
1 trials
TeleTai-Chi (virtual) Behavioral
1 trials
Investigator recommended exercise Behavioral
1 trials
Lactulose Drug
1 trials
ARFI ultrasound Device
1 trials
SHAPE measurement (Definity ultrasoud contrast agent) Drug
1 trials

US sites by state

Facility locations filed on Portal Hypertension trials. A trial with sites in several states counts in each.

Texas 4 trials
Pennsylvania 3 trials
Massachusetts 3 trials
Connecticut 3 trials
Missouri 2 trials
Michigan 2 trials
Florida 2 trials
Arizona 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Portal Hypertension page

10 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Portal Hypertension condition card totals 10 registered trials; most-linked intervention Sanvar® (vapreotide); top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.